AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy

Retrospective Clinical Study for Developing an AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy

The investigators aim to develop an AI-powered precision medicine system based on liquid biopsy that can comprehensively provide lung cancer patients with information on disease stage, histologic subtype, and presence of genetic mutations.

Inclusion Criteria (Patients)

• Republic of Korea nationality
• Age ≥ 30 years
• Lung cancer based on radiologic and/or histopathologic examination
• No prior diagnosis of any other cancer and no history of anticancer treatment before the date of blood sample collection

Exclusion Criteria (Patients)

• History of other cancers before blood collection
• Prior cancer treatment before blood collection
• Incomplete clinical data
• No consent for sample use

Inclusion Criteria (Healthy Controls):

• Republic of Korea nationality
• No history of any cancer
• Age ≥ 30 years

Exclusion Criteria (Healthy Controls):

• History of any malignancy
• Incomplete clinical information or no consent for sample use